Beige mice were inoculated intravenously with 1079 CFU of Mycobacterium avium 101. Among the untreated control mice, when the mean CFU per spleen increased to a level greater than 108, small numbers of organisms resistant to clarithromycin (CLARI) were isolated from some of the spleens; the frequency of CLARI-resistant mutants was estimated to be between 10-8 and 10-9. In mice treated with 200 mg of CLARI per kg of body weight six times weekly, however, CLARI-resistant organisms were isolated from the spleens of all mice examined after treatment for 8 weeks; the mean CFU per spleen and the frequency of resistant mutants were significantly greater than those of control mice and increased further after treatment for 16 weeks. The MICs of CIARI against the resistant organisms isolated from both control and treated mice were .512 ,ug/ml. Clarithromycin (CLARI) is one of the very few antimicrobial agents that show activity against Mycobacterium avium in vitro (4), in vivo (3), and in patients (1, 2). However, because of the enormous bacterial population in AIDS patients with disseminated M. avium infection (5) and because relapse with CLARI-resistant organisms after monotherapy with CLARI for more than 3 months has already been observed (1), the treatment of disseminated M. avium infection cannot depend upon CLARI or any single agent.
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The M. avium-infected beige mouse model has been widely used for experimental chemotherapy. However, the durations of treatment in previous studies have been limited to no more than 8 weeks, and no information with respect to the emergence of drug resistance has been available. We present results demonstrating the selection of CLARI-resistant mutants of M. avium in beige mice during monotherapy with CLARI for 16 weeks.
Beige mice were inoculated intravenously with 1079 CFU of M. avium 101. Before the organisms had been exposed to chemotherapy, they were susceptible to 1.0 ,ug of CLARI per ml, as determined on Mueller-Hinton agar medium enriched with 5% oleic acid-albumin-dextrose-catalase (Difco Laboratories) (OADC) (4). Five mice were sacrificed on the day following inoculation, and 10 were sacrificed on day 14. The remaining inoculated mice were allocated randomly to untreated control and CLARI-treated groups. CLARI was administered by esophageal cannula at a dosage of 200 mg/kg of body weight six times weekly; five to eight mice from each group were sacrificed after treatment with CLARI for 4, 8, and 16 weeks.
At the time animals were sacrificed, the spleens were removed and homogenized individually, and each was suspended in 3.5 ml of normal saline. Besides the total CFU count, which included the counting of both drug-susceptible and drug-resistant organisms, the undiluted and 10-1-and 10-2-diluted suspensions were also plated onto 5% OADCenriched Mueller-Hinton agar containing CLARI at a concentration of 8 ,ug/ml for the measurement of CFU of CLARI-resistant organisms. Colonies were enumerated after incubation at 37°C for 14 days; CLARI-resistant organ-* Corresponding author.
isms were defined as those growing on the CLARI-containing medium. With CLARI-treated mice, however, CLARI-resistant organisms were isolated from all of the spleens examined after treatment for 8 weeks. At this time, the mean number of CFU of resistant organisms per spleen was 101.92 ± 0.54 significantly greater (P < 0.05) than the number isolated from control mice (<101.31 0.°), and as shown in Table 1 , the difference in frequency of resistant organisms between control and treated groups was even greater (P < 0.001). After treatment for 16 weeks, both the mean number of CFU of resistant organisms (10397 ± 0-72) and the frequency of resistant organisms were very signifiantly greater than those after treatment for 8 weeks (P < 0.001).
The MICs of CLARI against the resistant organisms isolated from the spleens of both control and treated mice have been determined on CLARI-containing 5% OADCenriched Mueller-Hinton agar, and both were >512 ,ug/ml.
In conclusion, because CLARI-resistant mutants multiplied selectively during the course of monotherapy with CLARI, the M. avium-infected beige mouse provides a useful system for identifying the companion drugs that might prevent the emergence of organisms resistant to CLARI or other active drugs.
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